Dataset from A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older
收藏NIAID Data Ecosystem2026-05-02 收录
下载链接：
https://doi.org/10.25934/PR00009944
下载链接
链接失效反馈官方服务：
资源简介：
The study will evaluate the efficacy of Ad26.COV2.S in the prevention of molecularly
confirmed moderate to severe/critical coronavirus disease-2019 (COVID-19), as compared to
placebo, in SARS-CoV-2 seronegative adults in the double-blind phase and to describe COVID-19
outcomes, safety, and immunogenicity in the different study cohorts in open-label phase.
创建时间：
2025-02-10
